glp-1 obesity drug news oct 21 2025 Trump plan on weight loss drugs fails Americans Eli Lilly to seek approval

This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and tri-agonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects

Ungureanu, C

Versanis Bio announces completion of enrollment of the BELIEVE phase 2b study in patients with obesity(2023)

Important issues to review include nausea, vomiting, constipation, diarrhea, reflux, hydration status, protein intake, muscle preservation, diabetes medications, gallbladder symptoms, kidney function, history of pancreatitis, thyroid and family history considerations, and long-term maintenance strategy